May Thein
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
May Thein has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Ahmad Sadeghi
VA Greater Los Angeles Healthcare System, Radiation Oncology Service, 11301 Wilshire Blvd, Los Angeles, CA, 90073, USA
1 shared publication - Amar U. Kishan
Department of Radiation Oncology, University of California Los Angeles, Los Angeles, USA
1 shared publication - Carol J. Bennett
Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, CA; VA Greater Los Angeles Healthcare System at West Los Angeles, LA, CA
1 shared publication - Claudia Huiza
Department of Radiation Oncology, UCLA, 200 UCLA Medical Plaza, Suite B265, Los Angeles, CA, 90095-6951, USA
1 shared publication - Greg E. Gin
Long Beach, CA
1 shared publication - Homayoon Sanati
VA Long Beach Healthcare System, Internal Medicine Service, Hematology/Oncology Section, 5901 East 7th Street, Long Beach, CA, 90822, USA
1 shared publication
Latest Publications
- Open Access
- 1 April 2019
- Published by Springer Nature in BMC Cancer
- Vol. 19 (1) , 1-6
Systemic and tumor-directed therapy for oligometastatic prostate cancer: study protocol for a phase II trial for veterans with de novo oligometastatic disease
The treatment paradigm for metastatic hormone-sensitive prostate cancer (mHSPC) patients is evolving. PET/CT now offers improved sensitivity and accuracy in staging. Recent randomized trial data supports escalated hormone therapy, local primary tumor therapy, and metastasis-directed therapy. The impact of combining such therapies into a multimodal approach is unknown. This Phase II single-arm clinical trial sponsored and funded by Veterans Affairs combines local, metastasis-directed, and systemic therapies to durably render patients free of detectable disease off active therapy. Patients with newly-diagnosed M1a/b prostate cancer (PSMA PET/CT staging is permitted) and 1–5 radiographically visible metastases (excluding pelvic lymph nodes) are undergoing local treatment with radical prostatectomy, limited duration systemic therapy for a total of six months (leuprolide, abiraterone acetate with prednisone, and apalutamide), metastasis-directed stereotactic body radiotherapy (SBRT), and post-operative fractionated radiotherapy if pT ≥ 3a, N1, or positive margins are present. The primary endpoint is the percent of patients achieving a serum PSA of < 0.05 ng/mL six months after recovery of serum testosterone ≥150 ng/dL. Secondary endpoints include time to biochemical progression, time to radiographic progression, time to initiation of alternative antineoplastic therapy, prostate cancer specific survival, health related quality-of-life, safety and tolerability. To our knowledge, this is the first trial that tests a comprehensive systemic and tumor directed therapeutic strategy for patients with newly diagnosed oligometastatic prostate cancer. This trial, and others like it, represent the critical first step towards curative intent therapy for a patient population where palliation has been the norm. Clinicaltrials.gov identifier: NCT03298087 (registration date: September 29, 2017).
- 1 April 2019
- Published by Springer Nature in BMC Cancer
- Vol. 19 (1) , 1-6
Open AccessSystemic and tumor-directed therapy for oligometastatic prostate cancer: study protocol for a phase II trial for veterans with de novo oligometastatic disease
The treatment paradigm for metastatic hormone-sensitive prostate cancer (mHSPC) patients is evolving. PET/CT now offers improved sensitivity and accuracy in staging. Recent randomized trial data supports escalated hormone therapy, local primary tumor therapy, and metastasis-directed therapy. The impact of combining such therapies into a multimodal approach is unknown. This Phase II single-arm clinical trial sponsored and funded by Veterans Affairs combines local, metastasis-directed, and systemic therapies to durably render patients free of detectable disease off active therapy. Patients with newly-diagnosed M1a/b prostate cancer (PSMA PET/CT staging is permitted) and 1–5 radiographically visible metastases (excluding pelvic lymph nodes) are undergoing local treatment with radical prostatectomy, limited duration systemic therapy for a total of six months (leuprolide, abiraterone acetate with prednisone, and apalutamide), metastasis-directed stereotactic body radiotherapy (SBRT), and post-operative fractionated radiotherapy if pT ≥ 3a, N1, or positive margins are present. The primary endpoint is the percent of patients achieving a serum PSA of < 0.05 ng/mL six months after recovery of serum testosterone ≥150 ng/dL. Secondary endpoints include time to biochemical progression, time to radiographic progression, time to initiation of alternative antineoplastic therapy, prostate cancer specific survival, health related quality-of-life, safety and tolerability. To our knowledge, this is the first trial that tests a comprehensive systemic and tumor directed therapeutic strategy for patients with newly diagnosed oligometastatic prostate cancer. This trial, and others like it, represent the critical first step towards curative intent therapy for a patient population where palliation has been the norm. Clinicaltrials.gov identifier: NCT03298087 (registration date: September 29, 2017).